<?xml version="1.0" encoding="UTF-8"?>
<p>Over the past few years, conventional HCV therapy based on PEG-INFα/ribavirin has been replaced by direct-acting antiviral (DAA) drugs. These DAA therapies result in increased cure rates defined by virus clearance and improve liver inflammation and cirrhosis in HCV-infected patients (
 <xref rid="B36" ref-type="bibr">36</xref>–
 <xref rid="B38" ref-type="bibr">38</xref>). Effects of DAAs and HCV clearance on the restoration of different immune cell subsets including HCV-specific T cells, NK cells, and MAIT cells have been analyzed in patients (
 <xref rid="B39" ref-type="bibr">39</xref>–
 <xref rid="B43" ref-type="bibr">43</xref>). However, to the best of our knowledge, no study addressed the effect of DAA on γδ T cell composition.
</p>
